Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Weight Reduction in Bangladeshi Adults
NCT06616961Phase 3Not yet recruiting
- Sponsor
- Popular Medical College Hospital
- Start
- Nov 2024
- Primary completion
- Feb 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of semaglutide in obesity and Overweight, sponsored by Popular Medical College Hospital. Primary endpoint: Change in body weight at 26 weeks. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06616961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616961.